Boehringer's Spiriva Respimat under FDA review in asthma
This article was originally published in Scrip
Executive Summary
The FDA has accepted for review Boehringer Ingelheim’s new drug application (NDA) for Spiriva Respimat (tiotropium bromide) inhalation spray as a long-term once-daily add-on maintenance treatment for patients 12 years or older with asthma who remain symptomatic on at least inhaled corticosteroids (ICS).